FDA approves gefurulimab for myasthenia gravis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves gefurulimab for myasthenia gravis

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 3 min

Share

  • 1

    The FDA approved gefurulimab-gaks for adults with anti-AChR antibody-positive generalized myasthenia gravis.

  • 2

    Gefurulimab is a complement C5 inhibitor administered subcutaneously once weekly by autoinjector or prefilled syringe.

  • 3

    In the 260-participant PREVAIL trial, MG-ADL scores improved by 4.2 points with gefurulimab and 2.6 points with placebo at week 26.

  • 4

    Injection-site reactions occurred in 12% of gefurulimab recipients and 3% of placebo recipients in PREVAIL.

  • 5

    Gefurulimab carries a boxed warning for serious meningococcal infections and is available through a REMS requiring vaccination assessment.

Original Source(s)

Related Content